araag2/HINT huggingface dataset:
Clinical trial NCT02556203 (phase 3, status: terminated)
Conditions: transcatheter aortic valve replacement
ICD codes: Z79.890, Z96.693, Z47.1, Z95.4, Z96.691, Z96.692, T82.320S
Drugs: rivaroxaban (xarelto, bay59-7939), acetylsalicylic acid (asa), clopidogrel, rivaroxaban (xarelto, bay59-7939), vitamin k antagonist (vka)
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, CC(=O)OC1=CC=CC=C1C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O, ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
Reason stopped: 
    imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator
  
Eligibility criteria:

        Inclusion Criteria:

          -  Successful TAVR (Transcatheter Aortic Valve Replacement) of an aortic valve stenosis
             (either native or valve-in-valve)

               -  By iliofemoral or subclavian access

               -  With any approved/marketed device

        Exclusion Criteria:

          -  Atrial fibrillation (AF), current or previous, with an ongoing indication for oral
             anticoagulant treatment

          -  Any other indication for continued treatment with any oral anticoagulant (OAC)

          -  Known bleeding diathesis (such as but not limited to active internal bleeding,
             clinically significant bleeding, platelet count ≤ 50,000/mm3 at screening, hemoglobin
             level < 8.5 g/dL, active peptic ulcer or known gastrointestinal (GI) bleeding, history
             of intracranial hemorrhage or subdural hematoma)

          -  Any ongoing absolute indication for dual antiplatelet therapy (DAPT) at time of
             screening that is unrelated to the TAVR procedure

          -  Clinically overt stroke within the last 3 months

          -  Planned coronary or vascular intervention or major surgery

          -  Severe renal impairment (eGFR < 30 mL/min/1.73 m2) or on dialysis, or post-TAVR
             unresolved acute kidney injury with renal dysfunction stage 2 or higher

          -  Moderate and severe hepatic impairment (Child-Pugh Class B or C) or any hepatic
             disease associated with coagulopathy
Clinical trial NCT02558374 (phase 3, status: completed)
Conditions: open-angle glaucoma, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: ar-13324 ophthalmic solution 0.02%, timolol maleate ophthalmic solution 0.5% bid
SMILES: CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          1. 18 years of age or older

          2. Diagnosis of open angle glaucoma or ocular hypertension in both eyes

          3. Post-washout intraocular pressure >20mmHg and <30mmHg in 1 or both eyes at 2
             qualification visits

          4. Corrected visual acuity equivalent to 20/200

          5. Able to give informed consent and follow study instructions

        Exclusion Criteria:

          1. Clinically significant ocular disease

          2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure
             or narrow angles

          3. Unmedicated intraocular pressure ≥30mmHg

          4. Use of more than 2 ocular hypotensive medications within 30 days of screening

          5. Known hypersensitivity to any component of the formulation

          6. Previous glaucoma surgery or refractive surgery

          7. Ocular trauma within 6 months prior to screening

          8. Any ocular surgery or non-refractive laser treatment within 3 months prior to
             screening

          9. Recent or current ocular infection or inflammation in either eye

         10. Used ocular medication in either eye of any kind within 30 days of screening

         11. Mean central corneal thickness >620µm at screening

         12. Any abnormality preventing reliable applanation tonometry of either eye

         13. Clinically significant abnormalities in lab tests at screening

         14. Known hypersensitivity or contraindication to beta-adrenoceptor antagonists

         15. Clinically significant systemic disease

         16. Participation in any investigational study within 60 days prior to screening

         17. Used any systemic medication that could have a substantial effect in intraocular
             pressure within 30 days prior to screening

         18. Women who are pregnant, nursing, planning a pregnancy or not using a medically
             acceptable form of birth control
Clinical trial NCT02558400 (phase 3, status: completed)
Conditions: open-angle glaucoma, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: pg324 ophthalmic solution 0.02%/0.005%, netarsudil (ar-13324) ophthalmic solution 0.02%, latanoprost ophthalmic solution 0.005%
SMILES: CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. 18 years of age or older

          2. Diagnosis of open angle glaucoma or ocular hypertension in both eyes

          3. Unmedicated intraocular pressure >20mmHg and <36mmHg in both eyes at 2 qualification
             visits. Both eyes had to qualify at all qualification visits

          4. Corrected visual acuity equivalent to 20/200 Snellen or better

          5. Able to give informed consent and follow study instructions

        Exclusion Criteria:

          1. Clinically significant ocular disease

          2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure
             or narrow angles

          3. Unmedicated Intraocular pressure ≥36mmHg

          4. Use of more than 2 ocular hypotensive medications within 30 days of screening

          5. Known hypersensitivity to any component of the formulation

          6. Previous glaucoma surgery or refractive surgery

          7. Ocular trauma within 6 months prior to screening

          8. Any ocular surgery or non-refractive laser treatment within 3 months prior to
             screening

          9. Recent or current ocular infection or inflammation in either eye

         10. Used ocular medication in either eye of any kind within 30 days of screening

         11. Mean central corneal thickness >620µm at screening

         12. Any abnormality preventing reliable applanation tonometry of either eye

         13. Clinically significant abnormalities in lab tests at screening

         14. Clinically significant systemic disease

         15. Participation in any investigational study within 60 days prior to screening

         16. Used any systemic medication that could have a substantial effect on intraocular
             pressure within 30 days prior to screening

         17. Women who are pregnant, nursing, planning a pregnancy or not using a medically
             acceptable form of birth control
Clinical trial NCT02559895 (phase 3, status: completed)
Conditions: migraine disorders
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: ald403, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of migraine at ≤ 50 years of age (ICHD-II, 2004 Section 1)

          -  History of migraine ≥ 12 months with

               -  ≤ 14 headache days of which at least 4 have to be migraine days (migraine days
                  count as headache days) in each 28 day period in the 3 months prior to screening

               -  During the 28 days following the screening visit, the subject experiences ≤ 14
                  headache days of which at least 4 have to be migraine days (migraine days count
                  as headache days) as recorded in the eDiary

          -  No use of any botulinum toxin for migraine or for any other medical/cosmetic reasons
             requiring injections in the head, face, or neck 4 months prior to screening and during
             the 28 day period prior to randomization

          -  Headache eDiary was completed on at least 25 of the 28 days prior to randomization

        Exclusion Criteria:

          -  Confounding pain syndromes, e.g. fibromyalgia, complex regional pain syndrome or any
             pain syndrome that requires regular analgesia

          -  Psychiatric conditions that are uncontrolled and untreated, including conditions that
             are not controlled for a minimum of 6 months prior to screening

          -  History or diagnosis of complicated migraine (ICHD- II, 2004 Section 1), chronic
             tension-type headache, hypnic headache, cluster headache, hemicrania continua, new
             daily persistent headache, migraine with brainstem aura, sporadic and familial
             hemiplegic migraine

          -  Unable to differentiate migraine from other headaches

          -  Have any clinically significant concurrent medical condition

          -  Receipt of any monoclonal antibody treatment within 6 months of screening (within or
             outside a clinical trial)

          -  Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway
Clinical trial NCT02561806 (phase 3, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: ixekizumab, ustekinumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic plaque psoriasis for at least 6 months before baseline

          -  Failure, contraindication, or intolerability to at least 1 systemic therapy (including
             cyclosporine, methotrexate, or phototherapy)

          -  Psoriasis Area Severity Index (PASI) score at least 10 at screening and at baseline

          -  Participant must agree to use reliable method of birth control during the study; women
             must continue using birth control for at least 15 weeks after stopping treatment

        Exclusion Criteria:

          -  Predominant pattern of pustular, erythrodermic, and/or guttate forms of psoriasis

          -  History of drug-induced psoriasis

          -  Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks
             before baseline and during the study

          -  Have received systemic nonbiologic psoriasis therapy or phototherapy within 4 weeks of
             baseline, or have had topical psoriasis treatment within the 2 weeks of baseline

          -  Concurrent or recent use of any biologic agent within the following washout periods:
             etanercept <28 days; infliximab, adalimumab, or alefacept <60 days; golimumab <90
             days; rituximab <12 months; or any other biologic agent <5 half-lives prior to
             baseline

          -  Have prior use of ustekinumab, or have any condition or contraindication to
             ustekinumab that would preclude the participant from participating in this protocol

          -  Have previously completed or withdrawn from this study, participated in any other
             study with ixekizumab, have participated in any study investigating other interleukin
             (IL)-17 or IL-12/23 antagonists, or have received treatment with other IL-17 or
             IL-12/23 antagonists

          -  Have had a live vaccination within 12 weeks of baseline, or intend to have a live
             vaccination during the course of the study or within 15 weeks of completing treatment
             in this study

          -  Have had a vaccination with Bacillus Calmette-Guérin (BCG) within 12 months of
             baseline or intend to have vaccination with BCG during the course of the study or
             within 12 months of completing treatment in this study

          -  Have a known allergy or hypersensitivity to latex

          -  Have had any major surgery within 8 weeks of baseline or will require such during the
             study

          -  Have active or history of malignant disease within 5 years prior to baseline

          -  Significant uncontrolled disorder

          -  Ongoing infection or serious infection within 12 weeks of baseline; serious bone or
             joint infection within 24 weeks of baseline

          -  Are women who are lactating or breast-feeding
Clinical trial NCT02567279 (phase 3, status: terminated)
Conditions: anorexia nervosa
ICD codes: F50.00, F50.01, F50.02
Drugs: denosumab subcutaneous injections, placebo subcutaneous injections
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    great difficulties were encountered during recruitment, for fear denozumab. only 2 patients
    have been included since the study start.
  
Eligibility criteria:

        Inclusion criteria:

          -  Patients with a current AN defined by DSM-V criteria

          -  Being female

          -  Age over or equal to 18 years and less or equal to 40 years

             . For patients under 20 years of age, effective bone maturation (attested by a
             radiography of the hip)

          -  Agree to take contraception up to five months after the last injection of denosumab .

          -  Absence of pregnancy evidenced by an interview and a negative assay of human chorionic
             gonadotropin (ßhCG).

          -  Evidence of low BMD determined by Z-score value < -2 DS (at least one site (lumbar
             spine or total proximal femur)

          -  Signing an informed consent.

        Exclusion criteria:

          -  Not affiliated to a social security scheme or not being the beneficiary of such a
             scheme.

          -  Severe hepatic cytolysis with transaminase up to 5 times normal.

          -  Severe dental problems: in case of doubt an assessment by a dentist will be required
             before inclusion.

          -  Desire of pregnancy during the two years of follow-up study.

          -  Disease or treatment potentially responsible for secondary osteoporosis.

          -  Participant already treated with a molecule known to have an effect on bone

          -  Diabetes.

          -  Current hypocalcemia.

          -  Immunodeficiency.

          -  Cancer with bone lesions

          -  Patient on protectice measures (guardianship or trusteeship)

          -  Hypersensitivity to the active substance or to any of the excipients of Prolia®

          -  Unable to read and / or write and understand the methodology of the study

          -  Reporting relationship to the investigator

          -  Anticipate a long stay outside the region that would prevent compliance with the
             schedule of visits

          -  Participation to other biomedical research on health products

          -  Deprived of liberty

          -  Breastfeeding
Clinical trial NCT02567994 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: teneligliptin
SMILES: [H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCSC1)N1CCN(CC1)C1=CC(C)=NN1C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with Type 2 Diabetes Mellitus

          2. Adults aged ≥ 19 years old

          3. Patients with HbA1c 7%~11% at Screening and Run-in visit

        Exclusion Criteria:

        -
Clinical trial NCT02569242 (phase 3, status: completed)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: nivolumab, docetaxel/paclitaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Men & women ≥20 years of age

          -  Histologically confirmed unresectable advanced or recurrent esophageal cancer

          -  Refractory to or intolerant of standard therapy

          -  ECOG Performance Status score 0 or 1

          -  A life expectancy of at least 3 months

        Exclusion Criteria:

          -  Current or past history of severe hypersensitivity to any other antibody products

          -  Patients with multiple primary cancers

          -  Patients with any metastasis in the brain or meninx that is symptomatic or requires
             treatment

          -  Patients with active, known or suspected autoimmune disease
Clinical trial NCT02570490 (phase 3, status: completed)
Conditions: acute bacterial skin and skin structure infections
ICD codes: A49.9, G00.8, G00.9, J15.9, K65.2, A04.9, A05.9
Drugs: sodium fusidate, linezolid
SMILES: O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C, CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Adolescents between 12 to 18 years old must weigh >60 kg

          -  Patients diagnosed with ABSSSI with at least one systemic sign of infection

          -  Diagnosed with cellulitis, major cutaneous abscess, or wound infections (traumatic or
             surgical)

          -  Surface redness, edema or induration must be of a minimum surface area of 75 cm2, or
             extending ≥5 cm from the peripheral margin of the abscess

          -  Suspected or documented ABSSSI caused by a Gram-positive pathogen

        Exclusion Criteria:

          -  Involving a chronic diabetic foot infection (diabetic foot ulcer)

          -  Involving burns

          -  Involving an anatomical location (e.g. perirectal area) where the incidence of
             Gram-negative and/or anaerobic pathogen involvement is likely

          -  Documented bacteremia associated with the current ABSSSI

          -  Known severe renal impairment, as indicated by estimated CrCl <30 mL/min (by
             Cockcroft-Gault calculation)

          -  Evidence of significant liver disease: ALT >3x ULN, or direct bilirubin >ULN; known
             cirrhosis with decompensation (i.e. Child-Pugh Class B or C disease)
Clinical trial NCT02576509 (phase 3, status: active, not recruiting)
Conditions: hepatocellular carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: nivolumab, sorafenib
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Histologically confirmed advanced hepatocellular carcinoma, not eligible for surgical
             and/or locoregional therapies; or progressive disease after surgical and /or
             locoregional therapies

          -  Locoregional therapy for hepatocellular carcinoma (HCC) must be completed at least 4
             weeks prior to the baseline scan

          -  Child-Pugh Class A

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

        Exclusion Criteria:

          -  Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC

          -  Prior liver transplant

          -  Active, known, or suspected autoimmune disease
Clinical trial NCT02577003 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ipragliflozin, placebo, sitagliptin
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Inadequate glycemic control on diet/exercise therapy and sitagliptin monotherapy

          -  HbA1c ≥7.0% and ≤10.0% before study start

        Exclusion Criteria:

          -  History of Type 1 diabetes mellitus or a history of ketoacidosis

          -  History of any of the following medications: thiazolidinediones (TZD) and/or insulin
             within 12 weeks prior to study participation and sodium glucose cotransporter 2
             (SGLT2) inhibitors anytime

          -  Currently has a urinary tract infection or genital infection with subjective symptom
Clinical trial NCT02577016 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin, placebo, ipragliflozin
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Inadequate glycemic control on diet/exercise therapy and ipragliflozin monotherapy

          -  HbA1c ≥7.0% and ≤10.0% before study start

        Exclusion Criteria:

          -  History of type 1 diabetes mellitus or a history of ketoacidosis

          -  History of any of the following medications: thiazolidinediones (TZD) and/or insulin
             within 12 weeks prior to study participation, sitagliptin within 8 weeks prior to
             study participation.

          -  Currently has a urinary tract infection or genital infection with subjective symptom
Clinical trial NCT02579681 (phase 3, status: completed)
Conditions: multiple sclerosis, relapsing-remitting
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: dimethyl fumarate
SMILES: [H]\C(=C(\[H])C(=O)OC)C(=O)OC
Eligibility criteria:

        Key Inclusion Criteria:

          -  Must have a confirmed diagnosis of RRMS according to McDonald criteria (Polman,
             Reingold et al. 2005).

          -  Must have a baseline EDSS between 0.0 and 5.0, inclusive.

          -  Must have experienced at least 1 relapse within the 12 months prior to randomization,
             with a prior brain MRI demonstrating lesion(s) consistent with MS, or show evidence of
             gadolinium-enhancing lesion(s) of the brain on an MRI performed within the 6 weeks
             prior to randomization.

        Key Exclusion Criteria:

        Candidates will be excluded from study entry if any of the following exclusion criteria
        exist at the time of screening:

          -  Primary progressive, secondary progressive, or progressive relapsing MS, as defined by
             Lublin and Reingold (Lublin and Reingold 1996)

          -  Severe depression (MADRS score >34) (Montgomery and Asberg 1979)

          -  History of malignancy (except basal cell carcinoma that has been completely excised
             prior to study enrollment)

          -  An MS relapse that has occurred within the 30 days prior to inclusion AND/OR the
             participant has not stabilized from a previous relapse prior to inclusion.